Veradermics (MANE) Net Income towards Common Stockholders (2025 - 2026)
Veradermics (MANE) posted Net Income towards Common Stockholders of -$30.0 million for Q1 2026, down 105.81% on a QoQ basis from -$14.6 million in Q1 2025, and down 105.81% year-over-year from $516.7 million in Q1 2025.
Veradermics (MANE) Net Income towards Common Stockholders (2025 - 2026) Analysis & Trends
Veradermics' Net Income towards Common Stockholders history runs 2 years deep, the most recent figure standing at -$30.0 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 105.81% year-over-year to -$30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.6 million (changed N/A YoY) and the FY2025 annual result came in at -$83.4 million, down 205.36% from the prior year.
- Net Income towards Common Stockholders was -$30.0 million for Q1 2026 at Veradermics, down from -$14.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$14.6 million in Q1 2025 and bottomed at -$30.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Veradermics | 2.55 Bn | 2.55 Bn | - | -30.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.01 Mn |
| Mar 31, 2025 | -14.58 Mn |